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Surgical resection was the ﬁrst eﬀective treatment for breast cancer and remains the most important treatment modality for
curative intent. Reﬁnements in operative techniques along with the use of adjuvant radiotherapy and advanced chemotherapeutic
agents have facilitated increasingly focused breast cancer operations. Surgical management of breast cancer has shifted from
extensive and highly morbid procedures, to the modern concept obtaining the best possible cosmetic result in tandem with the
appropriate oncological resection. An ever-growing comprehension of breast cancer biology has led to substantial advances in
molecular diagnosis and targeted therapies. An emerging frontier involves the breast cancer microenvironment, as a thorough
understanding, while currently lacking, represents a critical opportunity for diagnosis and treatment. Collectively, these impro-
vements will continue to push all therapeutic interventions, including operative, toward the goal of becoming more focused,
targeted, and less morbid.
1.Introduction
Breast cancer is the most frequently diagnosed nonderma-
tological malignancy in women and ranks second only to
lung in cancer-related deaths [1]. While the incidence has
increased over the past decade, (Figures 1(a) and 1(b)) the
mortality rate of breast cancer has gradually declined [2, 3]
(Figure 2). This improved survival may stem from earlier
d e t e c t i o na sw e l la si m p r o v e dt h e r a p i e s[ 2, 3].
Surgical resection was one of the ﬁrst eﬀectivetreatments
for breast cancer and continues to play a critical role in the
treatment of this disease. A multidisciplinary approach is
now standard of care, involving a coordinated eﬀort with the
surgeon working in concert with the medical and radiation
oncologisttoachievethebestpossibleoutcomeforeachindi-
vidual. Improvements in both the quality and quantity of life
for victims of breast cancer can be attributed to the advances
made in each of these disciplines. As with all cancers, earlier
stage disease is more readily manageable than after signiﬁ-
cant advancement. It is these early-stage cancers in which the
mostsigniﬁcantimprovementsintheoperativemanagement
has occurred. Adoption of breast conservation surgery has
allowed an increased focus on the cosmetic outcome, during
a time that has also witnessed improved survival. This
represents a clear victory for breast cancer patients, which
needs to be extended to breast cancer of all stages.
2. HistoricalProgressionof the Surgical
Therapy of Breast Cancer
The Greek physician Galen is considered to be one of the
earliest advocates of surgical treatment, recommending wide
excision of breast tumors nearly 2000 years ago. Galen, like
his predecessor Hippocrates, also recognized that breast can-
cershouldbeconsideredasystemicdisease.Hippocratespro-
posed thatcancerswerethe resultof animbalance ofthe four
basic humours-blood, phlegm, and yellow and black bile. He
attributed an excess of black bile for postmenopausal women
havingagreaterincidenceofbreastcancer,aspremenopausal
women were relieved of this excess black bile with regular
menstruation [4]. Although primitive, this concept can be
extended to the current breast cancer treatment paradigm:2 International Journal of Breast Cancer
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Figure 1: Incidence rates of In situ (a) and Invasive (b) female breast cancer in the United States (1975–2008). American Cancer Society.
Breast Cancer Facts and Figures 2011-2012. Atlanta: American Cancer Society, Inc.
Figure 2: Mortality rate of female breast cancer, by race and
ethnicity (1975–2007). American Cancer Society. Breast Cancer
Facts and Figures 2011-2012. Atlanta: American Cancer Society, Inc.
systemic control of the disease at a molecular level, with local
control by surgical intervention. While we now know that
“blackbile”doesnotresultinbreastcancer,themosteﬀective
breast cancer management embodies this concept of breast
cancer as a systemic disease.
Early operations to treat breast cancer were primitive
and brutal. These procedures consisted of amputation fol-
lowed by cauterization, performed as rapidly as possible to
minimize hemorrhage. Unfortunately, patients surviving the
initial surgical procedure would all too frequently die of
fulminant sepsis. In the late 19th to early 20th century, the
advances of general anesthesia and antiseptic techniques fa-
cilitated more extensive procedures. Some of the most dra-
matic changes in surgical therapy for breast cancer were pio-
neered by William Steward Halstead [5]. His approach to the
mastectomy helped change the surgical therapy of the breast
from a simple amputation to a formal procedure. His tech-
nique, now termed the “radical mastectomy,” involved en
bloc resection of the breast, the pectoralis muscle, and the
axillary contents. This procedure was as eﬀective at initial
local tumor control as any early technique, with the signif-
icantadvancementofadramaticallydecreasedratesofrecur-
rence that plagued Halstead’s predecessors [5].
During Halstead’s era, prior to any understanding or ca-
pacity for early diagnosis, initial presentation of profoundly
advanced tumors was the norm. Accepting Halstead’s basic
principles, surgeons attempted progressively extensive resec-
tions for cure of widely disseminated tumors. This evolved
into dissection of the neck, abdomen, and even the medi-
astinum to remove diseased lymph nodes. Around the same
period, early methods for surgical staging were developed,
yielding a basic classiﬁcation of patients with tumors in
which radical mastectomy was potentially curative and those
with disseminated cancer not appropriate for attempted re-
section. However, it would not be until the 1940s when evi-
dence from preoperative staging brought the futility of what
had become “superradical mastectomies” into question [5].
Initial deviation from the tenets of Halstead began in
the late 1930s with an initial push for preservation of the
nondiseased breast tissue during cancer resection. Shortly
thereafter, postoperative radiotherapy was added for control
of local tumor recurrence, laying the groundwork for breast
conservation therapy (BCT) as we know it today [6].
Although BCT was not signiﬁcantly implemented in clinical
practice until the 1980s, the stage was set for the current
surgical treatment of breast tumors utilizing either BCT or
mastectomy.
3. Current Operative Management of
Breast Cancer
Optimal management of a patient with breast cancer
includes establishing a pathologic diagnosis prior to anyInternational Journal of Breast Cancer 3
deﬁnitive operative intervention. Formal surgical excision in
the operating room is rarely required to establish the diagno-
sis of breast cancer, as there are many alternative techniques
to obtain tissue for diagnosis. For example, much pathologic
information can be gained from small, 1-2mm “core” sam-
ples, allowing precise recommendations for treatment. The
diagnosis of breast cancer is conﬁrmed by histological evalu-
ation, and the tumor is assessed for grade as well as human
epidermal growth factor receptor 2 (HER2), estrogen, and
progesterone receptor status [7]. This information is critical
for optimal decision making regarding treatment options,
most importantly allowing for coordination of care for those
patients that will beneﬁt from neoadjuvant chemotherapy
prior to operative intervention [7].
After the diagnosis of breast cancer is established, pa-
tients are evaluated to determine the extent of the disease.
Standard of care includes bilateral mammography to identify
any suspicious areas in either breast that will impact sur-
gical management. Laboratory values that will assist in treat-
ment recommendations include complete blood count, liver
functiontests,andalkalinephosphatase.Therearenotestab-
lished tumor markers for breast cancers, although cancer
antigen (CA) 15-3 and CA 27-29 may be helpful when ele-
vated. Additional imaging studies to evaluate for metastatic
disease are obtained depending on signs and symptoms of
the patient, as well as the clinical stage at presentation. A
bone scan is indicated if the patient has localized bony pain
or elevated alkaline phosphatase, chest imaging is indicat-
ed for pulmonary symptoms, and abdominal imaging by
computerized tomography is indicated for abnormal liver
functional tests or abdominal symptoms. A review of the
acquired data, including pathology, laboratory assessment,
and imaging, allows the multidisciplinary team to make re-
commendations for deﬁnitive management of the patient
with breast cancer. Those patients with evidence of advanced
disease are typically managed medically with preoperative
chemotherapy, prior to any deﬁnitive surgical management.
Locoregional(operative)controlofbreastcancerremains
the mainstay of treatment. Surgical treatment should allow
the patient to be involved in the decision-making process,
with the surgeon providing information about all surgical
options available. Deﬁnitive surgical management typically
involves breast conservation (BCT) or mastectomy. Local
excision alone is at times acceptable, usually in the setting
of elderly or otherwise debilitated patients without adjuvant
radiation. This decision must be carefully weighed and based
on evaluation of tumor aggressiveness and comorbid con-
ditions of the patient.
There are two required components for BCT. First,
tumorsmustberesectablewithapathologicallyclearmargin,
that is, a surrounding margin of breast parenchyma without
disease. Secondly, patients undergoing partial mastectomy
typically receive whole breast irradiation to achieve local
control in the breast. Tumor size must be suﬃciently small
relative to the entire breast, such that the appearance of the
breast is cosmetically acceptable following partial mastec-
tomy. Additionally, all suspicious ﬁndings on imaging must
be resectable with the partial mastectomy. The presence of
diﬀuse highly concerning microcalciﬁcations on mammog-
raphy is a contraindication to BCT. Pregnancy and a history
of previous chest irradiation do not allow BCT, as they are
contraindications to the requisite postoperative radiother-
apy. Positive margins after BCT require a repeat attempt at
excision or completion mastectomy to achieve clear margins.
Findings of involved margins with partial mastectomy
signiﬁcantly increase the chance of disease recurrence [8].
Mastectomy is indicated for the curative resection of
tumors (i.e., absence of metastatic disease) not amenable to
BCT, and for those patients that do not want to consider
conservation even though they meet criteria. The modern
version of this procedure is termed the “modiﬁed radical
mastectomy,” which entails removal of the breast, its under-
lying pectoralis fascia, and axillary contents, performed for
more extensive disease.
Inadditiontoresectionoftheprimarytumor,allinvasive
breast cancers require assessment of axillary lymph nodes
for tumor invasion. The ipsilateral axillary lymph nodes are
theoretically the ﬁrst site that breast cancer is expected to
spread, with the sentinel nodes representing the ﬁrst group
ofnodesatriskforinvasion.Assessmentoftheaxillarynodes
includessentinellymphnodebiopsy(SLNB)duringlumpec-
tomy, or at the time of mastectomy. The SLNB represents
another hallmark of targeted surgical therapy. Injection of a
dyeand/orradio-isotopeintothebreastallowsthesurgeonto
identify the ﬁrst (“sentinel”) lymph node draining the tumor
basin. Involvement of axillary nodes is considered regional
disease (not metastatic) and is usually followed by complete
axillary node resection [8] .N o d a ls t a t u sp r o v i d e sc r i t i c a l
staging information necessary for the proper selection of ad-
juvant therapy. Furthermore, negative ﬁndings after a prop-
erly performed SLNB allow a patient to avoid the potential
for signiﬁcant morbidity after axillary dissection. An all too
common and often debilitating complication of this pro-
cedure is upper extremity lymphedema [9].
Insitubreastcancerisaneoplasmthatiscompletelycon-
tained within its basement membrane. This early neoplasm
can be derived from a duct or lobule and is, therefore, re-
ferred to as lobule carcinoma in situ (LCIS) or ductal car-
cinoma in situ (DCIS). LCIS of the breast requires special
consideration, as it is considered a marker for the future
developmentofinvasivebreastcancer.Theriskofdeveloping
invasive cancer is low, and if it occurs, histology tends to
be favorable. For this group of women, LCIS is managed by
appropriate monitoring without additional intervention. Al-
ternatively, hormonal therapy can be administered for the
purpose of breast cancer prevention. The potential adverse
reactions of these medications must be considered and bal-
anced with the presumed risk reduction.
In contrast to LCIS, the diagnosis of DCIS requires treat-
ment for local control at the time of diagnosis. With the
development of techniques for the earlier diagnosis of breast
cancer, DCIS is the only diagnosis in approximately 15% of
newly diagnosed breast cancer patients. This ﬁnding must
be addressed, as the survival rates for treated DCIS are near
100%, but the development of invasive disease occurs in up
to 30% of patients with untreated DCIS [10]. Treatment op-
tions include breast conservation with partial mastectomy
and radiation, or total mastectomy. Although DCIS is often4 International Journal of Breast Cancer
found in conjunction with an invasive carcinoma, treatment
for the invasive component takes precedence and dictates
both surgical and medical management. In contrast to man-
agement of invasive disease, those patients with DCIS usu-
ally do not require axillary dissection, as axillary nodal in-
v o l v e m e n ti np a t i e n t sw i t hp u r eD C I Si su n u s u a l .A sa
small number will have axillary involvement, sentinel node
evaluation should be performed if mastectomy is the chosen
operation for local control [11].
4. Breast Cancer Surgery and Chemotherapy
Starting in the mid-twentieth century, most notably in the
lab of Bernard Fisher, early chemotherapeutic agents were
being analyzed for use in the preoperative setting. The use of
neoadjuvant chemotherapy (NACT) prior to an attempted
surgical resection represents a dramatic improvement in
breast cancer therapy, addressing the systemic aspect of this
disease.NACTisindicatedforlocallyadvancedtumorsorin-
ﬂammatory breast cancer. Locally advanced breast cancer
entailslargetumorsorthosethatinvadethechestwallorskin
(T4) or have spread to the axillary nodes (N2 or N3) [12].
An excellent response to chemotherapy merits reassess-
mentofthepatienttoensureaconcomitantclinicalandradi-
ological response. Eradication of all tumor after neoadjuvant
chemotherapy is termed pathological complete response
(pCR), strictly deﬁned as the absence of invasive cancer
from the breast and axilla on pathological assessment in re-
sponse to chemotherapy [13]. While achieving pCR has been
found to increase long-term survival [14] ,aw i d er a n g eo f
local recurrence rates (2.6–22.6%) after BCT following neo-
adjuvanttherapy hasbeennoted [15].Onerecentstudyindi-
cates that Her2 positive and positive axillary lymphadenopa-
thy may predict this recurrence after pCR [15]. While high
risk populations certainly merit close postoperative surveil-
lance for recurrent disease. Appropriately placing those pa-
tients achieving excellent response to chemotherapy into the
algorithm for the surgical management of breast cancer re-
quires further assessment. Improved methods are needed
to predict those tumors best amenable to downstaging to
BCT, as certain patients may in fact be better candidates for
mastectomy.Furthermore, strict criterion deﬁning the medi-
cal management of successful pCR is also needed. Molecular
tests such as the 21 gene (oncotype DX) and 70 gene
(mammaPrint) assay [7], that provide tumor-speciﬁc scores
reﬂecting risk of recurrence, may become useful in this
scenario.
The eﬀectiveness of NACT for locally advanced disease
eventually led to the use of pre-operative treatment in an at-
tempt to “downstage” even more advanced cancer to a scope
amenable to treatment by mastectomy [12]. A recent exten-
sion of these principles is the use of chemotherapy to down-
stage tumors, in order to avoid mastectomy altogether in lieu
of BCT. NACT is indicated for tumors meeting all criteria
for breast conservation (see above) except for tumor size.
An excellent response in this scenario has now allowed the
option for BCT in a patient who would have required a mas-
tectomy.
5. Recent Advances in the SurgicalTherapy of
Breast Cancer
Most of the recent advances in the surgical management of
breast cancer follow the basic template of ever more conser-
vative surgical resections. The ﬁrst involves operative breast
cancer therapy with a concomitant focus on breast recon-
struction, known as oncoplastic breast surgery [16]. This
trend represents another advancement made possible by
the reﬁnements in the use of postoperative radiation, the
same concept that led to the advent of BCT. Oncoplastic
surgeryentails the use of plastic surgery techniques to restore
cosmesis and natural symmetry, ideally during cancer resec-
tion [16]. Plastic surgery techniques utilized include breast
augmentationandreduction,ﬂaps,implants,andexpanders,
on both the diseased and the normal breast if necessary to
achieve the desired symmetry. Indications are still widely
debated, but appropriate candidates are those that have suﬀ-
icient residual breast after the oncological resection to facil-
itate the necessary reconstruction [6].
One of the most recent advances in surgical therapy in-
volves management of the positive sentinel lymph node bio-
psy (SLNB). Traditionally, a positive SLNB represents an
absolutemandateforacompleteaxillarydissection.Substan-
tial morbidity, not unlike that which was seen in the days
of Halstead, all too often follows. However, a recent study
has demonstrated that high-risk patients with small tumors
(T1-T2) and limited lymph node spread, who are able to
receive radiotherapy, do not beneﬁt further from complete
axillary lymph node removal [17]. Simply stated, survival for
small breast tumors with limited spread does not improve
after axillary dissection in older individuals or those with
signiﬁcant medical problems. This early work has found that
this subset of patients suﬀer more from the complications of
theprocedurethanbeneﬁt.Theadjuvantradiotherapythera-
py given for this early-invasive disease seems to provide most
of the survival beneﬁt.
Arecenttrendincludingsurgeryascancerpreventionhas
gained wide acceptance. Contralateral prophylactic mastec-
tomy (CPM) has been found to decrease the risk of devel-
opment of a cancer in the disease-free breast in women at
high risk. Those women harboring a BRCA mutation or a
strongfamilyhistoryofbreastcancermaybeconsideredcan-
didates for prophylactic bilateral mastectomy. As mentioned
previously, with the diagnosis of LCIS, the risk of devel-
oping an invasive breast cancer is equal in both breasts, such
that bilateral mastectomy may be necessary for true risk re-
duction. Many women, in an otherwise low-risk category,
also opt for CPM after a newly diagnosed breast cancer. This
usuallyinvolvesfearofdevelopingdiseaseinthecontralateral
breast. While recent data suggests an increased overall as well
as disease-free survival after CPM [18], the debate is ongoing
regardingtheappropriateindicationsforCPM.Thisisinfact
anextensiveoperationwiththepotential forsigniﬁcantmor-
bidity. The decision to take such a measure is formidable.
Similarly, the quest to identify the population beneﬁting the
most from this intervention must be equally rigorous.International Journal of Breast Cancer 5
6. Surgery andBreast Cancer Metastasis
The most successful operative management of metastasis is
prophylactic: appropriate screening for detection of suspi-
cious lesions of the breast, followed by appropriate local con-
trol to minimize the potential for metastatic dissemination.
This is reﬂected in recent trends showing improved survival
of breast cancer patients, as screening and early intervention
has translated into improved outcomes. After the diagnosis
and completion of treatment of a primary breast cancer, sur-
veillance for recurrence or metastatic spread ensues. Follow-
up entails focused clinical and laboratory assessment, and
mammography to detect new or recurrent lesions.
The discovery of metastatic disease at any point merits
a complete reevaluation. Traditionally, surgical intervention
was avoided in the patient harboring metastatic disease, due
to a perceived lack of beneﬁt. Only those patients with ex-
tremely limited metastatic lesions were considered for ther-
apeutic resection. For the most part, patients found to have
metastatic disease were deferred to induction chemotherapy
inthehopesofanexcellentresponseandprolongationoflife.
Most traditional use of surgical intervention in the set-
tingofmetastaticdiseasewasforpalliativepurposes,ateither
the primary tumor site or any distant metastatic lesions. For
example, resection of the primary tumor was considered
for persistent infection, bleeding, or general diﬃculty main-
taining cleanliness. However, many recent studies have been
able to challenge this practice of avoiding intervention on
the primary tumor in the setting of metastatic disease. Early
studies indicate that resection of a primary breast lesion
may increase survival in the setting of limited metastasis.
This eﬀect probably stems from more eﬀective and speciﬁc
chemotherapy, but randomized trials are needed to deﬁne
both the optimal candidates and indications for this inter-
vention. However, the signiﬁcance of the early ﬁndings of re-
duced need for chemotherapy, improved quality of life, and
evenlong-termcureswiththeconcomitantresectionof(lim-
ited) metastatic lesions cannot be overstated [19].
Operative intervention for metastasic lesions is typically
palliative, involving the treatment of a symptomatic mass.
This may entail bypassing an obstructing metastatic lesion
in the bowels, utilizing a normal segment of bowel to allow
free ﬂow of intestinal contents. However, aggressive resection
of metastatic lesions for curative intent has gained favor in
recent years. The best studied is the resection of metastatic
lesions to the lung, in which long-term success and even
some cures have been reported. The patients most amenable
to metastasectomy are those with limited metastatic burden
(oligometastases)withhormonallyresponsivetumors.Oper-
ative characteristics include smaller lesions in a location that
facilitates complete removal [20].
It is a well-known fact that the most common site of
breast cancer metastasis is the bone, with breast cancer
being the leading cause of bone metastasis of any cancer in
women. The lung, liver, and brain are other common sites
of metastasis. However, it has recently been demonstrated
that the basic breast cancer subtypes (Luminal A, luminal B,
HER-2 positive, and basal) diﬀerentially target certain sites
for metastasis. For example, the HER-2 positive and triple
negativesubtypeshavebeenshowntopreferentiallymetasta-
size to the brain over the other subtypes [21]. While this rep-
resents an interesting ﬁnding, further investigation is needed
to translate this data into clinical practice. For example,
knowledge of the presence of a basal phenotype in a high risk
patient may merit more aggressive, organ-speciﬁc followup.
7. Surgery andthe Breast
Cancer Microenvironment
Surgical resection of breast cancer is absolutely curative if
performed while the primary tumor is contained. Escape
of tumor cells from the primary lesion completely changes
therapeutic management, expectations, as well as outcomes.
Chemotherapy becomes the primary hope for cure as
opposed to surgical intervention. Interestingly, some early
stagetumors,allofwhichwerepreviouslyassumedtobeself-
contained, have been shown to harbor the capacity for sys-
temic tumor dissemination. While there is no method to ac-
curately predict which tumors have this devastating capacity,
certainfactorssuchaslargetumors,youngerageatdiagnosis,
vascularinvasion,andnodalinvolvementhavebeenfoundto
be associated with a high risk of developing distal metastasis
after appropriate treatment [22, 23].
The best treatment option currently available is eﬀective
loco-regional control of the primary tumor. The surgeon’s
primary focus at the time of resection is obtaining clear mar-
gins. Most studies have found that obtaining at least a 2
millimeter margin for invasive and in situ breast cancer
best minimizes the chance of local recurrence [24, 25]. This
threshold has consistently led to reduced local recurrence
rates, while balancing the potential for an overly aggressive
resection. Eﬀective local control removes the nidus for both
local and distant recurrence, emphasizing the management
of the primary tumor on the systemic aspect of the disease.
This eﬀectisexempliﬁed bythe signiﬁcant increasein distant
metastasis rates and subsequent survival with the devel-
opment of a local recurrence of a resected breast tumor [22–
26].
Further evidence that breast cancer, even at its early sta-
ges, can be a systemic disease can be found in animal studies
and early analysis in cancer patients. Utilizing PCR and im-
munohistochemistry, increased cancer-related cells have
beendemonstratedinthesystemiccirculationduetosurgical
manipulation [27–30]. Needle biopsies of primary tumors
haveevenbeenfoundtoresultinincreasedratesofnodalme-
tastasis [31, 32]. Tumor cells that break oﬀ from the primary
site and enter the systemic circulation are referred to as
circulating tumor cells (CTCs). While the CTCs were ﬁrst
described over a century ago, the technology for their detec-
tion has only recently become reliable. Current methods al-
low for the enrichment of CTCs by antibody-mediated tar-
getingoftheepithelialcelladhesionmarker(EpCAM).While
the clinical usefulness of CTC assessment is controversial,
some consider that greater than ﬁve CTCs is the breaking
point for a poor prognosis in breast cancer [33, 34].
Detection of CTC has been used to demonstrate sig-
niﬁcant shedding of putative tumor cells into the systemic
circulation during surgical manipulation [35]. While this6 International Journal of Breast Cancer
shedding is known to occur in both breast and lung cancers
[36], the functional result and ability of these cells to suc-
cessfully migrate and seed distant sites is not known [37].
Furthermore,somehypothesizethatthetissuetraumaresult-
ant from needle or operative manipulation may lead to the
expression of an invasive or metastatic phenotype [38]. This
alteration may lead to cancer progression or the release of
CTCs, respectively [39]. Pathways implicated in these ef-
fects are normal and appropriate wound healing responses,
such as those involved in inﬂammation and angiogenesis
[38]. With the continued technological improvement for the
detectionofCTCs,determiningtheclinicalrelevanceofthese
eﬀects may become possible. The assessment of CTCs could
one day provide the basis for highly speciﬁc real-time bio-
psies, yielding a strong potential for the modiﬁcation of sur-
gical techniques and traditional indications. The capacity to
harvest and analyze CTCs could become a key feature of in-
dividual tumor proﬁling, allowing for patient-speciﬁc ther-
apies to further reduce the current complication proﬁle of
today’s interventions [8, 40].
8. Conclusion
Surgical intervention is currently the best hope for deﬁnitive
cure of breast cancer. Even so, recent advances represent sig-
niﬁcant steps away from the extensive resections performed
by Halstead and his predecessors. While these early attempts
successfully decreased local recurrence rates, advances in the
treatment of breast cancer as a systemic disease were needed
to facilitate long-term cures. Continued improvements in
earlydiagnosisviabreastimaging,advancedprognostictests,
patient-speciﬁc molecular diagnosis, and the development
of targeted chemotherapeutic agents provide hope for im-
proved survival rates. By doing so, breast cancer therapy will
become more focused, increasing eﬃcacy and reducing com-
plications of all the treatment disciplines. This will move the
bar closer to the ultimate goal of transforming breast cancer
into an easily targeted, readily manageable disease.
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